Monoclonal Antibodies (mAbs) Market [By Product Type (Fully Human, Murine, Chimeric); By Production System (Mammalian Cell Culture, Microbial Fermentation); By Indication (Cancer, Inflammation, Cardiovascular diseases, Transplant Rejection, Respiratory and Infectious diseases); By Technology Platforms (Transgenic-Mouse, Antibody Drug Conjugate, Phage-Display); By Target Mechanism of Action (CGRP, HER2, CTLA4, TNF alpha, EGFR, VEGF, Anti CD, Anti IL, IgGs, PD-1/PD-L1), By Care Delivery Setting; By Drug Types & By Region]: Market Size & Forecast, 2017 - 2026

报告摘要

2017年全球单克隆抗体（MAB）市场的价值为88.2亿美元，预计预测期内的复合年增长率为6.1％，达到2026年的1489亿美元。单克隆抗体是具有一价亲和力的抗体由祖传细胞的克隆的相同免疫细胞产生。单克隆抗体主要用于诊断领域，治疗癌症，自身免疫疾病，炎症疾病和传染病等疾病，以及蛋白质纯化。

全球马伯市场mainly driven by an active pipeline, wherein many mAbs are at the pre-clinical stage and various stages of clinical trials. Also, increase in the research and development activities coupled with favorable government policies attribute to the market growth. Furthermore, the surge in the demand for personalized medicine, increasing prevalence of cancer and other chronic diseases, and rising awareness about the latest medical therapies among medical professional and patients would further boost the market. However, mono-specificity of mAbs limits its extensive use in the field of therapeutics. Also, the manufacturing processes of mAbs are very robust, wherein even a minor change in the antigen structure can affect the functionality of the mAbs. The other factors which impede the market growth include extensive time consumption, high costs of manufacturing, quality control and patient compliance. Furthermore, price correction, emerging targets such as central nervous system disorders and new delivery strategies for mAbs provide opportunities for market growth in the near future.

单克隆抗体（MABS）市场范围

By Product Tpe	通过生产系统	通过指示	通过技术平台	By Target Mechanism of Action	By Route of Administration	用药物类型	按地区
全人类 Murine ch Humanized	Mammalian Cell Culture 微生物发酵	癌症 炎 心血管疾病 Transplant Rejection 呼吸道 传染性疾病	转基因小鼠 抗体药物缀合物 噬菌体展示	CGRP HER2 CTLA4. tnf alpha. EGFR VEGF 抗CD. Anti-IL IgGS，PD-1 / PD-L1	皮下来的 静脉	品牌生物学 生物纤维单模	北美 欧洲 亚太 拉美 中东和非洲

了解有关此报告的更多信息：request for sample pages

细分分析

全球单克隆抗体（MABS）市场是在产品类型，生产系统，指示，技术平台，目标机制的基础上进行分割，毒品类型和地理位置，通过给药途径，护理送达，护理送达。在产品类型的基础上，市场分为全人，小鼠，嵌合和人性化。根据生产系统，市场分为哺乳动物细胞培养和微生物发酵。在迹象的基础上，市场进一步分为癌症，炎症，心血管疾病，移植抑制，呼吸系统和传染病。在技​​术平台的基础上，市场被分段为转基因小鼠，抗体药物缀合物和噬菌体展示。基于目标作用机制，该市场分叉进入CGRP，HER2，CTLA4，TNFα，EGFR，VEGF，抗CD，抗IL，IgG和PD-1 / PD-1。在护理交付环境的基础上，市场被分割为初级保健和专业护理。通过行政途径，市场分为皮下和静脉内。基于药物类型，市场进一步分类为品牌生物制剂和生物仿制物。该报告分析了跨北美，德国，亚太地区，拉丁美洲和中东和非洲的全球市场。 Geographically, North America accounted for the largest share in the global monoclonal antibody (mAb) market in 2017.

Competitive Landscape

该行业的主要球员包括PFizer，Inc。，Glaxosmithkline Plc，Novartis AG，​​Merck＆Co.，Inc。，Eli Lily＆Co.，Astazeneca，Amgen，Inc。，Abbott Laboratories，Thermo Fisher Scientific，Inc。，Bistro-Myers Squibb。Mylan N.v.，Daiichi Sankyo Company，Ltd。，Bayer AG，Hoffmann-La Roche Ltd.和Novo Nordisk A / s。市场参与者采用了各种战略，如新产品开发，新产品发布，以及风险投资等方面的风险投资，以获得市场上部。